Factor-Xa inhibitors protect against systemic oxidant damage induced by peripheral-ischemia reperfusion

Basit Öğe Kaydı
dc.contributor.authorCaliskan, Ahmet
dc.contributor.authorYavuz, Celal
dc.contributor.authorKarahan, Oguz
dc.contributor.authorYazici, Suleyman
dc.contributor.authorGuclu, Orkut
dc.contributor.authorDemirtas, Sinan
dc.contributor.authorMavitas, Binali
dc.date.accessioned2024-04-24T16:02:22Z
dc.date.available2024-04-24T16:02:22Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractFactor-Xa inhibitors are often used for prophylaxis and for the treatment of thrombotic vascular disorders. However, it is not known whether they are beneficial during the recanalization of the thrombotic vascular segment and during tissue reperfusion. Herein, we describe an animal study that was designed to investigate the possible protective effects and antioxidant properties of factor-Xa inhibitors. Forty rats were included in the study and were randomly divided into five equal groups. The first group served as a control group from which we obtained basal oxidant and antioxidant parameters. Peripheral ischemia was induced in the second group (sham group) for 6 h, and plasma levels of nitrogen oxide (NOx), prolidase and malondialdehyde (MDA) were obtained after 30 min of reperfusion. The sham group did not receive any drugs. Oral rivaroxaban (3 mg/kg) was administrated to Group III, intraperitoneal enoxaparin sodium (250 U/kg) was administrated to Group IV, and intraperitoneal bemiparine sodium (250 U/kg) was administrated to Group V 1 week prior to the induction of peripheral ischemia (for 6 h)-reperfusion. After 30 min of reperfusion, blood samples were obtained and NOx, prolidase and MDA levels in these groups were detected, and the rats were sacrificed. NOx levels were statistically similar (p > 0.05) between Groups I, II, III, IV, and V (20.7 +/- A 10.4, 17.4 +/- A 9.7, 25.9 +/- A 24.2, 27.0 +/- A 11.9, 23.3 +/- A 17.3 mu mol/L, respectively). MDA levels were significantly lower (p < 0.05) in Groups III (rivaroxaban), IV (enoxaparin sodium), and V (bemiparine sodium) (24.9 +/- A 11.9, 25.9 +/- A 4.4, 25.4 +/- A 10.8 mu mol/L, respectively) when compared with the sham group (Group II) (75.6 +/- A 24.3 mu mol/L). Prolidase levels were higher (p > 0.05) in the ischemia reperfusion groups (659.2 +/- A 130.6 in II (sham), 1,741.0 +/- A 1,530.6 in III (rivaroxaban), 2,453.8 +/- A 1,590.4 in IV (enoxaparin sodium), and 889.2 +/- A 574.7 U/g in V (bemiparine sodium) than in the control group (144.6 +/- A 131.8 U/g). Ischemia-reperfusion events may occur in prothrombotic disorders. During these events, prophylactic or therapeutic factor-Xa inhibitors can protect against thrombosis and oxidative reperfusion injury. The new oral factor-Xa inhibitor, rivaroxaban, appears to provide the same antioxidant support as injectable low molecular weight heparins (LMWHs).en_US
dc.identifier.doi10.1007/s11239-013-1019-4
dc.identifier.endpage468en_US
dc.identifier.issn0929-5305
dc.identifier.issn1573-742X
dc.identifier.issue4en_US
dc.identifier.pmid24218342
dc.identifier.scopus2-s2.0-84899928188
dc.identifier.scopusqualityQ1
dc.identifier.startpage464en_US
dc.identifier.urihttps://doi.org/10.1007/s11239-013-1019-4
dc.identifier.urihttps://hdl.handle.net/11468/14760
dc.identifier.volume37en_US
dc.identifier.wosWOS:000334506700012
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Thrombosis and Thrombolysis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIschemia-Reperfusion Injuryen_US
dc.subjectOxidative Damageen_US
dc.subjectLmwhen_US
dc.subjectFactor Xa Inhibitorsen_US
dc.subjectLmwhsen_US
dc.subjectRivaroxabanen_US
dc.titleFactor-Xa inhibitors protect against systemic oxidant damage induced by peripheral-ischemia reperfusionen_US
dc.titleFactor-Xa inhibitors protect against systemic oxidant damage induced by peripheral-ischemia reperfusion
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu